ACHL - Achilles Therapeutics EPS misses by $6.83

Achilles Therapeutics (ACHL): Q1 GAAP EPS of -$8.38 misses by $6.83.Cash and cash equivalents: Cash and cash equivalents were $159.3 million as of March 31, 2021 as compared to $177.8 million as of December 31, 2020, not including $160.6 million in net proceeds from the IPO which closed on April 6, 2021. The Company anticipates that its existing cash and cash equivalents plus the IPO proceeds are sufficient to fund its planned operations into the second half of 2023, including full funding of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.Press Release

For further details see:

Achilles Therapeutics EPS misses by $6.83